Common Stock, par value $0.001 per share
- Symbol
- UPB
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Quarterly Report · 10-Q
Upstream Bio, Inc.
UPBNASDAQEQUITYCurrent
Quarterly Report
Company context
Upstream Bio is a clinical-stage biotechnology company developing treatments for severe inflammatory respiratory diseases. The Company is developing verekitug, the only known antagonist currently in clinical development that targets and inhibits the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple inflammatory pathways. With more than 500 participants treated with verekitug across its clinical development programs and positive Phase 2 results in chronic rhinosinusitis with nasal polyps (CRSwNP) and severe asthma, verekitug has a substantial body of clinical evidence supporting its advancement into Phase 3 development in both diseases. Verekitug is also being evaluated in an ongoing Phase 2 trial in chronic obstructive pulmonary disease (COPD). Upstream Bio is focused on leveraging verekitug’s differentiated mechanism, potency, and potential for extended dosing to develop a treatment that may deliver best-in-class efficacy and quarterly dosing for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.
Current securities
Recent company filings
Registered securities in this filing
UPSTREAM BIO, INC. · 10-Q · Filed 2026-05-13
As-filed source
As filedOpen full document ↗